CAR-T Cell Therapy for Relapsed Lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your lymphoma has come back after treatment or no longer responds to treatment (relapsed or refractory)
- Your cancer cells express CD19 (a protein doctors can identify through a biopsy)
- You have received at least one prior cancer treatment
- You are not pregnant and do not have active hepatitis B, hepatitis C, or HIV
- You have an adequate number of healthy immune cells (specifically a certain type called naïve T-lymphocytes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy designed to target and destroy cancer cells that have the CD19 marker. It may help people with large B-cell lymphoma that has relapsed or not responded to standard treatments.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are modified to find and attack lymphoma cells with CD20 or CD30 markers. It is for people whose lymphoma has not responded to standard treatments or has returned after treatment.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.